The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index; 7 of the 18 sources its claims cite were checked for support.
Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome
Open accessAbstract
Study question: What is the recommended assessment and management of those with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference? Summary answer: International evidence-based guidelines address prioritized questions and outcomes and include 254 recommendations and practice points, to promote consistent, evidence-based care and improve the experience and health outcomes in PCOS. What is known already: The 2018 International PCOS Guideline was independently evaluated as high quality and integrated multidisciplinary and consumer perspectives from 6 continents; it is now used in 196 countries and is widely cited. It was based on best available, but generally very low- to low-quality, evidence. It applied robust methodological processes and addressed shared priorities. The guideline transitioned from consensus-based to evidence-based diagnostic criteria and enhanced accuracy of diagnosis, whilst promoting consistency of care. However, diagnosis is still delayed, the needs of those with PCOS are not being adequately met, the evidence quality was low, and evidence-practice gaps persist. Study design, size, and duration: The 2023 International Evidence-based Guideline update re-engaged the 2018 network across professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Extensive evidence synthesis was completed. Appraisal of Guidelines for Research and Evaluation II (AGREEII)-compliant processes were followed. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation, and ultimately recommendation strength, and diversity and inclusion were considered throughout. Participants/materials, setting, and methods: This summary should be read in conjunction with the full guideline for detailed participants and methods. Governance included a 6-continent international advisory and management committee, 5 guideline development groups, and paediatric, consumer, and translation committees. Extensive consumer engagement and guideline experts informed the update scope and priorities. Engaged international society-nominated panels included paediatrics, endocrinology, gynaecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, obesity care, public health, and other experts, alongside consumers, project management, evidence synthesis, statisticians, and translation experts. Thirty-nine professional and consumer organizations covering 71 countries engaged in the process. Twenty meetings and 5 face-to-face forums over 12 months addressed 58 prioritized clinical questions involving 52 systematic and 3 narrative reviews. Evidence-based recommendations were developed and approved via consensus across 5 guideline panels, modified based on international feedback and peer review, independently reviewed for methodological rigour, and approved by the Australian Government National Health and Medical Research Council. Main results and the role of chance: The evidence in the assessment and management of PCOS has generally improved in the past 5 years but remains of low to moderate quality. The technical evidence report and analyses (∼6000 pages) underpin 77 evidence-based and 54 consensus recommendations, with 123 practice points. Key updates include the following: (1) further refinement of individual diagnostic criteria, a simplified diagnostic algorithm, and inclusion of anti-Müllerian hormone levels as an alternative to ultrasound in adults only; (2) strengthening recognition of broader features of PCOS including metabolic risk factors, cardiovascular disease, sleep apnoea, very high prevalence of psychological features, and high risk status for adverse outcomes during pregnancy; (3) emphasizing the poorly recognized, diverse burden of disease and the need for greater healthcare professional education, evidence-based patient information, improved models of care, and shared decision-making to improve patient experience, alongside greater research; (4) maintained emphasis on healthy lifestyle, emotional well-being, and quality of life, with awareness and consideration of weight stigma; and (5) emphasizing evidence-based medical therapy and cheaper and safer fertility management. Limitations and reasons for caution: Overall, recommendations are strengthened and evidence is improved but remains generally low to moderate quality. Significantly greater research is now needed in this neglected, yet common condition. Regional health system variation was considered and acknowledged, with a further process for guideline and translation resource adaptation provided. Wider implications of the findings: The 2023 International Guideline for the Assessment and Management of PCOS provides clinicians and patients with clear advice on best practice, based on the best available evidence, expert multidisciplinary input, and consumer preferences. Research recommendations have been generated, and a comprehensive multifaceted dissemination and translation programme supports the guideline with an integrated evaluation programme.
Overview
CoChat Summary
TL;DR
The 2023 international evidence-based guideline update provides 254 recommendations and practice points for PCOS assessment and management, including 77 evidence-based and 54 consensus recommendations plus 123 practice points. It emphasizes refined diagnosis (including AMH as an alternative to ultrasound in adults only), broader metabolic/cardiovascular/psychological risk recognition, lifestyle and shared decision-making, and evidence-based fertility management, while noting evidence remains low to moderate quality.
Key findings
- The guideline includes 254 recommendations and practice points; a technical report of ∼6000 pages underpins 77 evidence-based and 54 consensus recommendations, with 123 practice points.
- Diagnostic updates: PCOS should be diagnosed using the 2018 criteria requiring 2 of clinical/biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovaries; AMH can now be used instead of ultrasound in adults only, but not in adolescents; when irregular cycles and hyperandrogenism are present, ultrasound or AMH are not required for diagnosis.
- PCOS prevalence is 10%–13% globally and is associated with increased risks including cardiovascular disease, impaired glucose tolerance/type 2 diabetes, obstructive sleep apnoea independent of BMI, endometrial hyperplasia/cancer, high prevalence of moderate to severe depressive/anxiety symptoms, and higher-risk pregnancy.
- Management recommendations include healthy lifestyle for all, no single diet or exercise type shown superior, COCP as first-line pharmacological treatment for menstrual irregularity/hyperandrogenism, metformin primarily for metabolic features, letrozole as first-line ovulation induction, gonadotrophins or laparoscopic ovarian surgery as second-line, and IVF as third-line where first- or second-line therapies fail.
Methods
- The 2023 update re-engaged the 2018 network across 39 professional and consumer organizations covering 71 countries, with 5 guideline development groups (56 members), 20 meetings and 5 face-to-face forums over 12 months, and 52 systematic plus 3 narrative reviews. The abstract reports 58 prioritized clinical questions; the Materials and methods section reports 55.
- AGREEII-compliant processes were followed, and the GRADE framework was applied across evidence quality, feasibility, acceptability, cost, implementation, and recommendation strength, with diversity and inclusion considered throughout.
- Evidence synthesis and meta-analysis were completed; recommendations were developed and approved via consensus across 5 guideline panels, modified after international feedback and peer review, independently reviewed for methodological rigour, and approved by the Australian Government National Health and Medical Research Council.
Limitations
- The paper states that recommendations are strengthened and evidence has improved but remains generally low to moderate quality, and that significantly greater research is needed in this neglected yet common condition.
- The paper states that regional health system variation was considered and acknowledged, with a further process for guideline and translation resource adaptation provided; it also notes that certainty of evidence varied across outcomes and reflects the lowest certainty for critical outcomes.
- The text makes evident that this article is a summary and refers readers to the full guideline and technical report for detailed participants and methods; it also contains a minor internal inconsistency in the reported number of prioritized clinical questions (58 vs 55).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 66 Not valid · 4 Not checked · 80 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“PCOS aetiology is complex; clinical presentation is heterogeneous with reproductive, metabolic, and psychological features. 1,2”
What the sources say
- Supportedcites [1] Teede, 2010, Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan, BMC Med source
The Introduction’s “Clinical features of PCOS” section explicitly describes PCOS as heterogeneous, with presentations that include psychological problems, reproductive manifestations, and metabolic implications. The Appendix also lists features in all three categories. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [2] Azziz, 2016, Polycystic ovary syndrome, Nat Rev Dis Primers source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Healthcare professionals should be aware of the high prevalence of moderate to severe depressive symptoms and depression in adults and adolescents with PCOS”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The cardiometabolic risk in female first-degree relatives of women with PCOS remains inconclusive.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Current evidence demonstrates no difference in foetal abnormality rates between letrozole or clomiphene citrate ovulation induction or natural conception.”
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Flutamide and bicalutamide have an increased risk of severe liver toxicity.”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
37 more claims
Create a free account to see all 156 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 109
- It may state two separate claims as one. 32
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Abstract
“Twenty meetings and 5 face-to-face forums over 12 months addressed 58 prioritized clinical questions involving 52 systematic and 3 narrative reviews.”
§ Materials and methods
“With international meetings over 12 months 55 prioritized clinical questions involved 52 systematic and 3 narrative reviews”
Citations
Cites
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005 · cited 2×
“1,2 3-5 Clinical practice in the assessment and management of PCOS remains inconsistent, with ongoing key evidence-practice gaps.”
Self-citationTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., International PCOS Network, Andersen, M., et al. (2018) · Human Reproduction · doi:10.1093/humrep/dey256 · Cited by 1,593
Self-citationTeede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565
Self-citationGibson-Helm, M., Teede, H., Dunaif, A., & Dokras, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2963 · Cited by 428 · cited 1×
“Women internationally experience delayed diagnosis and dissatisfaction with care.(3-5) Clinical practice in the assessment and management of PCOS remains inconsistent, with ongoing key practice evidence gaps.”
BackgroundSelf-citationDokras, A., Saini, S., Gibson-Helm, M., Schulkin, J., Cooney, L., & Teede, H. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.04.011 · Cited by 218 · cited 5×
“Here, we summarize recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS.”
InfluentialSelf-citationBellver Pradas, J., Casanova, C., Garrido Puchalt, N., Lara, C., Giménez, J. R., Martínez, A. P., & Serra, V. (2013) · Repository of Digital Objects for Teaching Research and Culture (University of Valencia) · doi:10.1016/j.fertnstert · Cited by 192
Mol, B. W., Lai, S., Rahim, A., Bordewijk, E. M., Wang, R., van Eekelen, R., Gurrin, L. C., Thornton, J. G., van Wely, M., & Li, W. (2023) · Research Integrity and Peer Review · doi:10.1186/s41073-023-00130-8 · Cited by 154 · cited 1×
“Category includes evidence-based (sufficient evidence in PCOS) or consensus (insufficient evidence in PCOS, also evidence in general or relevant populations was considered) recommendations and accompanying practice points (implementation considerations) (Table 1).”
Self-citationA checklist to assess Trustworthiness in RAndomised Controlled Trials (TRACT checklist)
Mol, B. W., Lai, S., Rahim, A., Bordewijk, E. M., Wang, R., Eekelen, R. V., Gurrin, L. C., Thornton, J. G., Wely, M. V., & Li, W. (2023) · doi:10.21203/rs.3.rs-2119486/v1 · Cited by 149
Self-citationTeede, H., Gibson-Helm, M., Norman, R. J., & Boyle, J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2978 · Cited by 93 · cited 6×
“The 5 GDGs covered: (1) Screening, diagnostic and risk assessment and life stage; (2) Psychological features and models of care; (3) Lifestyle management; (4) Management of nonfertility features; and (5) Assessment and management of infertility.”
InfluentialSelf-citation
Cited by
Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M., Patil, M., Rees, D. A., Berry, L., Cree, M. G., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00717-8 · Cited by 534
Self-citationInternational evidence-based recommendations for polycystic ovary syndrome in adolescents
Peña, A. S., Witchel, S. F., Boivin, J., Burgert, T. S., Ee, C., Hoeger, K. M., Lujan, M. E., Mousa, A., Oberfield, S. E., Tay, C. T., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-03901-w · Cited by 107
“The full 2023 Guideline update provides recommendations in five areas: screening, diagnosis, and risk assessment; psychological features; lifestyle; management of nonfertility features; and infertility [8, 9].”
InfluentialSelf-citationNeven, A. C. H., Forslund, M., Ranasinha, S., Mousa, A., Tay, C. T., Peña, A. S., Oberfield, S. E., Witchel, S. F., Teede, H. J., & Boyle, J. A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae125 · Cited by 73
Self-citationPrevalence, Phenotypes, and Comorbidities of Polycystic Ovary Syndrome Among Indian Women
Ganie, M. A., Chowdhury, S., Malhotra, N., Sahay, R. K., Bhattacharya, P. K., Agrawal, S., Jabbar, P. K., Suri, V., Rozati, R., Sreenivas, V., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.40583 · Cited by 85
Fitz, V., Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad762 · Cited by 70
Self-citation
Metadata
- Authors
- Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., Joham, A. E., the International PCOS Network, Arlt, W., Azziz, R., Balen, A., Bedson, L., Berry, L., Boivin, J., Boyle, J., Brennan, L., Brown, W., Burgert, T., Busby, M., Ee, C., Garad, R. M., Gibson-Helm, M., Harrison, C., Hart, R., Hopkins, K., Hirschberg, A. L., Ho, T., Hoeger, K., Jordan, C., Legro, R. S., Li, R., Lujan, M., Ma, R., Mansfield, D., Marsh, K., Mocanu, E., Mol, B., Mormon, R., Norman, R., Oberfield, S., Patel, M., Pattuwage, L., Peña, A., Redman, L., Rombauts, L., Romualdi, D., Shah, D., Spritzer, P. M., Stener-Victorin, E., Tehrani, F. R., Thangaratinam, S., Thondan, M., Vanky, E., Wijeyaratne, C., Witchel, S., Yang, D., Yildiz, B., Alesi, S., Alur-Gupta, S., Avery, J., Khomami, M. B., Benham, J., Bidstrup, H., Chua, S. J., Cooney, L., Coster, T., Ee, C., Fitz, V., Flanagan, M., Forslund, M., Jiskoot, G., Kazemi, M., Kempegowda, P., Louwers, Y., Lujan, M., Melin, J., Melson, E., Mengistu, Y. B., Naderpoor, N., Neven, A., Pastoor, H., Rocha, T., Sabag, A., Subramanian, A., & Tan, K.
- Affiliations
- Monash Health (AU)
- National Health and Medical Research Council Centre for Research Excellence in Women's Health in Reproductive Life , Australia
- University of Pennsylvania (US)
- Oulu University Hospital (FI)
- UNSW Sydney (AU)
- Pennington Biomedical Research Center , Louisiana State University, Baton Rouge, LA , United States
- Cardiff University (GB)
- Eastern Health (AU)
- National Health and Medical Research Council (AU)
- Pennington Biomedical Research Center (US)
- Corresponding author
- Teede, Helena J
- ORCID
- Teede, Helena J
- Tay, Chau Thien
- Dokras, Anuja
- Moran, Lisa J
- Piltonen, Terhi T
- Costello, Michael F
- Mousa, Aya
- Joham, Anju E
- Arlt, Wiebke
- Azziz, Ricardo
- Balen, Adam
- Brennan, Leah
- Brown, Wendy
- Burgert, Tania
- Garad, Rhonda M
- Harrison, Cheryce
- Hart, Roger
- Hirschberg, Angelica Lindén
- Ho, Tuong
- Hoeger, Kathleen
- Jordan, Cailin
- Legro, Richard S
- Li, Rong
- Mansfield, Darren
- Marsh, Kate
- Mocanu, Edgar
- Mol, Ben
- Oberfield, Sharon
- Patel, Malika
- Pattuwage, Loyal
- Peña, Alexia
- Rombauts, Luk
- Romualdi, Daniela
- Shah, Duru
- Spritzer, Poli Mara
- Tehrani, Fahimeh Ramezani
- Thangaratinam, Shakila
- Vanky, Eszter
- Wijeyaratne, Chandrika
- Witchel, Selma
- Yang, Dongzi
- Alesi, Simon
- Alur-Gupta, Snigdha
- Avery, Jodie
- Khomami, Mahnaz Bahri
- Benham, Jamie
- Bidstrup, Hugh
- Chua, Su Jen
- Cooney, Laura
- Fitz, Victoria
- Forslund, Maria
- Jiskoot, Geranne
- Kempegowda, Punith
- Louwers, Yvonne
- Melin, Johanna
- Melson, Eka
- Naderpoor, Negar
- Neven, Adriana
- Pastoor, Hester
- Sabag, Angelo
- Subramanian, Anuradhaa
- Tan, Katrina
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-08
- Volume
- 189
- Issue
- 2
- Pages
- G43-G64
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W4385827828
- Cited by
- 525
- References
- 11
- Citations by year
- 2026: 229 · 2025: 177 · 2024: 102 · 2023: 16
- FWCI
- 125.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Journal of Endocrinology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc)
- ePrints Soton (University of Southampton) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc)
- Funders
- National Health Medical Research Council (APP1171592)
- American Society for Reproductive Medicine
- Endocrine Society
- European Society for Human Reproduction and Embryology
- Society for Endocrinology
- Commonwealth Government of Australia
- Medical Research Future Fund (MRFCRI000266)
- NHMRC
- Royal Australasian College of Physicians
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, PCOS diagnosis, PCOS management, diagnostic criteria, infertility, hyperandrogenism, insulin resistance, obesity, customer engagement, shared decision-making, knowledge-practice gap, guideline recommendations, AGREE II, GRADE, multidisciplinary care, health outcomes, quality of life
- MeSH terms
- Adult, Australia, Female, Humans, Polycystic Ovary Syndrome, Pregnancy, Quality of Life, Risk Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. https://app.cochat.ai/papers/10.1093/ejendo/lvad096
- The paper
- Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., Joham, A. E., the International PCOS Network, Arlt, W., Azziz, R., Balen, A., Bedson, L., Berry, L., . . . Tan, K. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvad096
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.